Sanofi's Wayrilz Approved in US for Immune Thrombocytopenia
Ticker: SNYNF · Form: 6-K · Filed: Sep 3, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-approval, pharmaceuticals, regulatory
TL;DR
Sanofi's Wayrilz gets US green light for ITP, a new weapon against rare autoimmune disease.
AI Summary
On August 29, 2025, Sanofi announced that its drug Wayrilz (tirabrutinib) received US approval as the first BTK inhibitor for immune thrombocytopenia (ITP). This approval marks a significant advancement in treating ITP, a rare autoimmune disorder.
Why It Matters
This approval provides a new, targeted treatment option for patients suffering from immune thrombocytopenia, potentially improving outcomes for a condition with limited therapeutic choices.
Risk Assessment
Risk Level: low — This filing is an informational report (6-K) about a drug approval and does not contain significant financial or operational changes that would typically increase risk.
Key Players & Entities
- Sanofi (company) — Registrant and drug developer
- Wayrilz (drug) — Approved medication
- tirabrutinib (drug) — Generic name for Wayrilz
- August 29, 2025 (date) — Date of press release
- immune thrombocytopenia (medical_condition) — Condition treated by Wayrilz
FAQ
What is the specific indication for which Wayrilz was approved in the US?
Wayrilz was approved in the US as the first BTK inhibitor for immune thrombocytopenia (ITP).
What is the generic name of the drug Wayrilz?
The generic name of Wayrilz is tirabrutinib.
When was the press release announcing the approval filed?
The press release was dated August 29, 2025, and is attached as Exhibit 99.1 to this 6-K filing.
What type of drug is Wayrilz?
Wayrilz is a BTK inhibitor.
What is the filing form used by Sanofi for this report?
Sanofi is filing a Form 6-K report.
Filing Stats: 182 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2025-09-03 12:44:17
Filing Documents
- d52080d6k.htm (6-K) — 8KB
- d52080dex991.htm (EX-99.1) — 26KB
- g52080g0730220735399.jpg (GRAPHIC) — 3KB
- g52080g0731001059118.jpg (GRAPHIC) — 1KB
- 0001193125-25-194750.txt ( ) — 40KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: September 3, 2025 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3